Literature DB >> 14313477

CHEMICAL AND IMMUNOCHEMICAL STUDIES WITH A DIALYZABLE ENCEPHALITOGENIC COMPOUND FROM BOVINE SPINAL CORD.

A NAKAO, E ROBOZ-EINSTEIN.   

Abstract

Entities:  

Keywords:  ANTIBODIES; ANTIGENS; CATTLE; ENCEPHALOMYELITIS; ENCEPHALOMYELITIS, ALLERGIC; EXPERIMENTAL LAB STUDY; GUINEA PIGS; NERVE TISSUE PROTEINS; NEUROCHEMISTRY; RATS; SPINAL CORD

Mesh：

Substances：

Year:  1965        PMID： 14313477     DOI： 10.1111/j.1749-6632.1965.tb20201.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  6 in total

1.  Enzyme activities associated with demyelinating phase of canine distemper. II. Plasmalogenase.

Authors:  D N McMartin; L A Horrocks; A Koestner
Journal:  Acta Neuropathol       Date:  1972       Impact factor: 17.088

2.  Protection of rats from experimental allergic encephalomyelitis with antiserum to guinea-pig spinal cord.

Authors:  R A Hughes
Journal:  Immunology       Date:  1974-04       Impact factor: 7.397

3.  Fractionation of encephalitogenic polypeptides from bovine spinal cord by gel filtration in phenol--acetic acid--water.

Authors:  P R Carnegie; C E Lumsden
Journal:  Immunology       Date:  1967-02       Impact factor: 7.397

4.  The role of serum factors in the suppression of experimental allergic encephalomyelitis: evidence for immunoregulation by antibody to the encephalitogenic peptide.

Authors:  I A MacPhee; M J Day; D W Mason
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

5.  Experimental allergic encephalomyelitis. Isolation of basic proteins and polypeptides from central nervous tissue.

Authors:  P R Carnegie; B Bencina; G Lamoureux
Journal:  Biochem J       Date:  1967-11       Impact factor: 3.857

6.  Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids.

Authors:  I A MacPhee; F A Antoni; D W Mason
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.